Nifedipine (versus unexposed)

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14357
R56841		 Parazzini, 1998 Caesarean section 2nd and/or 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 0.70 [0.40;1.10] 72/128   77/124 149 128
ref
Total 1 studies 0.70 [0.42;1.16] 149 128
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Parazzini, 1998Parazzini, 1998 0.70[0.40; 1.10]1491280%ROB confusion: lowROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0 RCTRCT 0.70[0.42; 1.16]149128 -NAParazzini, 1998 1 Type of controls unexposed, sickunexposed, sick 0.70[0.42; 1.16]149128 -NAParazzini, 1998 1 Tags Adjustment   - Randomisation  - Randomisation 0.70[0.42; 1.16]149128 -NAParazzini, 1998 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 0.70[0.42; 1.16]149128 -NAParazzini, 1998 1 All studiesAll studies 0.70[0.42; 1.16]149128 -NAParazzini, 1998 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.70[0.42; 1.16]149128 -NAParazzini, 1998 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Alavifard (Caesarean delivery (versus Hydrala ...Alavifard (Caesarean delivery (versus Hydralazine)) 1.02[0.48; 2.04]-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Alavifard (Caesarean delivery (versus Labetalol))Alavifard (Caesarean delivery (versus Labetalol)) 1.06[0.47; 2.22]-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Shekhar - GESTATIONAL HYPERTENSION (Caesarean ...Shekhar - GESTATIONAL HYPERTENSION (Caesarean section) 0.98[0.75; 1.30]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT4 Firoz (Caesarean section (versus hydralazine iv))Firoz (Caesarean section (versus hydralazine iv)) 0.85[0.56; 1.29]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Firoz (Caesarean section (versus Labetalol iv))Firoz (Caesarean section (versus Labetalol iv)) 1.23[0.76; 1.98]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Bellos (Cesarean delivery (Randomized control ...Bellos (Cesarean delivery (Randomized controlled trial and Cohort studies)) 0.85[0.56; 1.29]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos (Cesarean delivery (Randomized control ...Bellos (Cesarean delivery (Randomized controlled trial only)) 0.85[0.56; 1.29]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 0.70[0.42; 1.16]NaN%128----Parazzini, 1998 10.510.01.0